Respicardia Stock

respicardia.comHealthcare / Other HealthcareFounded: 2006Funding to Date: $153.45MM

Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health.

Register To Buy and Sell Shares

For more details on financing and valuation for Respicardia, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Respicardia’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Respicardia.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Timothy Hauch
Chief Financial Officer
Todd Goblish
Vice President, Research & Development
Peter Sommerness
Chief Executive Officer
Linda Nelson
Vice President, Clinical Affairs
Bonnie Labosky
Chief Executive Officer, Board Member & President
Frank Piskolich JD
General and IP Counsel
Robin Germany MD
Chief Medical Officer

Board Members

Kristine Johnson
Affinity Capital Management
Thomas Weldon
Accuitive Medical Ventures
William Abraham MD
Kirk Nielsen
Versant Venture Management
Wilfred Jaeger MD
Three Arch Partners
Zack Scott MD
Revelation Partners
Kevin Wasserstein
Versant Venture Management
Scott Ward
Edward Andrle
Sorin

Frequently Asked Questions About Respicardia’s Stock

plusminus
Can you buy Respicardia’s stock?
Respicardia is not publicly traded on NYSE or NASDAQ in the U.S. To buy Respicardia’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Respicardia’s stock?
Yes, you can sell stock of a private company like Respicardia. Forge can help you sell your Respicardia stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Respicardia’s stock price?
Respicardia is a privately held company and therefore does not have a public stock price. However, you may access Respicardia’s private market stock price with Forge Data.
plusminus
What is Respicardia’s stock ticker symbol?
Respicardia does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Sorin Group Takes $20M Stake in Respicardia, With Option to Acquire
Respicardia Inc. has received a $20 million investment from Sorin Group and sold select European distribution rights for its implantable sleep apnea device to the Italian medical-device company.
Sorin drops $20m on stake in Respicardia
Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
Updated on: Apr 15, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.